Welcome to the ONgoing Telmisartan Alone in combination with Ramipril Global Endpoint Trial (ONTARGET®) website for healthcare professionals. Here you can read about The ONTARGET® Trial Programme1 which consists of two large-scale, parallel trials ONTARGET® and TRANSCEND®. Together, these trials represent the largest cardiovascular clinical trial programme undertaken to investigate the role of an angiotensin II receptor blocker (ARB) and an angiotensin-converting enzyme (ACE) inhibitor alone or in combination to prevent stroke, myocardial infarction, and hospitalization for chronic heart failure.1-4
This website contains the latest information about The ONTARGET® Trial Programme, including:
- why the ONTARGET® and TRANSCEND® trials are being conducted
- how the trials have been designed
- what patients have been included and excluded
- when the first results are likely to be available
- who the principal investigators are
What is ONTARGET®?
The ONTARGET® Trial Programme, including the parallel ONTARGET® and TRANSCEND® trials, is a landmark clinical investigation in cardiovascular protection. Find out more here.
Why is ONTARGET® Important?
As the largest cardiovascular outcome ARB trial in a broad cross-section of high-risk patients, results from ONTARGET® have the potential to influence positively cardiovascular morbidity and mortality among a wide range of patient populations. Find out more here.
Why telmisartan?
Telmisartan was chosen for The ONTARGET® Trial Programme because it is a powerful angiotensin II receptor blocker (ARB) with proven 24-hour efficacy and placebo-like tolerability. Find out more here.
Calendar
Tools and Downloads
My Alerts
You will shortly be able to create your own personal alerts service bringing the latest ONTARGET® news and updates direct to your inbox. Watch this space for more information.
